Sunlight on the CMTA

Tom Dubensky, the CMTA’s Venture Arm, and Shark Tooth

Line drawing of three overlapping circles, holding a heart, a seedling growing from a coin, and a shark fin, with one person where all three overlap.

Tom Dubensky sat on the board of the Charcot-Marie-Tooth Association (CMTA) for at least eight years, spoke for the charity when it launched a venture-philanthropy arm to take stakes in CMT biotech companies, and is now listed as a scientific adviser to Shark Tooth Biotech, the company the CMTA later invested in. Until at least October 15, 2026, Shark Tooth’s website described him as on the CMTA’s board; by October 19 it called him a “Former CMTA Board Member.” The CMTA’s own board page and its latest tax return do not, yet the CMTA’s Winter 2025 report lists him as one of three special advisers to its board.

None of this shows wrongdoing. It shows how closely the people who set the CMTA’s research and investment direction overlap with the companies it funds, and why the charity should say plainly who decides what, and when people step aside.

Who Is Tom Dubensky?

Thomas W. Dubensky, Jr., PhD, is a biotech executive whose career has been in cancer immunotherapy and infectious disease. The CMTA’s own 2022 speaker biography describes him as a CMTA board member and the founding CEO of the oncology-focused Tempest Therapeutics, with earlier roles at Viagene, Chiron, Onyx, Cerus and Immune Design.1 In May 2024 he became chief executive of ImmuneSensor Therapeutics, a privately held company developing drugs that act on the cGAS-STING immune pathway for autoimmune disease, inflammation and cancer.2

None of the CMTA material I found describes a personal or family connection to CMT, as many of its directors’ biographies do. I asked him about this on October 12, 2026. He had not replied by the November 13 deadline.

Eight Years on the Board

The CMTA’s annual tax returns list Dubensky as a director every year from 2017 through 2024. He is not on the 2016 return.3 The charity’s Summer 2019 newsletter also lists “Thomas W. Dubensky, Jr., PhD” on its board.4

The 2024 return gives no end date for him, so the public record does not say when, or whether, he left.

He is not on the 2025 return, filed on May 15, 2026, which lists 17 voting directors.5 He is not on the CMTA’s current Board of Directors page either.6 The 2024 return gives no end date for him, so the public record does not say when, or whether, he left.

One caution: the 2025 return also leaves out Pat Verduin, who is still on the CMTA’s board page. So his absence from that return is not, on its own, proof of when he stepped down. The CMTA’s other records don’t settle it. Its Winter 2025 report, uploaded to its website in January 2026, lists Dubensky as one of three special advisers to the board.7 Its board page doesn’t list him in any archived version I checked: in September 2025 it named no special advisers, and since at least April 2026 it has named two, Bruce Chizen and Alan Korowitz.8 So, around the time the report called him a special adviser, the board page didn’t list him, and Shark Tooth’s website called him a board member.

The Venture-Philanthropy Arm

On November 16, 2023, the CMTA announced that it had joined a seed funding round for Armatus Bio, a company developing a gene therapy for CMT1A. The release quoted “Thomas Dubensky, Ph.D., a CMTA board member,” who said Armatus was the first investment from the CMTA’s new venture-philanthropy arm, which would make selected early-stage investments in biotech companies developing CMT therapies and work alongside its STAR research program.9 The release did not say how much the CMTA invested.

A charity buying a stake in a company is a different thing from a charity making a research grant. A grant pays for research. An investment can also pay the charity back if the company succeeds, and it ties the charity’s finances to that company’s fortunes. The CMTA’s 2025 return reports $403,066 in program-related investments at year-end, up from $281,041 a year earlier.10

Shark Tooth

Shark Tooth Biotech’s website says it was founded in September 2024 by David Apple, whose son has CMT1A; Delaware records show it was incorporated there on September 23, 2024, and registered in California two days later. Its California filings name Apple as its only officer, serving as chief executive, chief financial officer and secretary, and list no directors; since July 2026 he has also been its agent for service of process.11 Apple told me he first discussed the idea of Shark Tooth with the CMTA board in February 2024.12 Apple has been a CMTA director since April 2023.13 The CMTA’s 2025 return reports a $248,763 equity investment in Shark Tooth as a transaction with a “35%+ controlled entity of a board member.”14 Its audited statements describe the investment as a Simple Agreement for Future Equity funded from donations directed to Shark Tooth research, and say the director with an ownership interest recused himself from considering and approving it.15

That leaves about $154,000 of the CMTA’s program-related investments that are not Shark Tooth. The return does not say what they are. Armatus is the only other CMTA investment I have found announced.

When I checked Shark Tooth’s Our Team page on October 15, 2026, it listed Dubensky among its scientific advisers as “CEO ImmuneSensor” and “Board of CMTA.” By October 19, the second label read “Former CMTA Board Member.” Archived copies show the page before the change and after it. It lists John Svaren, PhD, as “Chair CMTA SAB.”16 Svaren chairs the CMTA’s Scientific Advisory Board, which the return says oversees the selection of research grantees, and he is listed as a CMTA board member on the 2025 return.17

What the Record Does and Doesn’t Show

Here is what the documents establish:

  • Dubensky was a CMTA director from at least 2017 through 2024.
  • He was the public face of the CMTA’s move into equity investing in 2023.
  • The CMTA later took an equity stake in a company founded by another of its directors.
  • Dubensky and a current CMTA director, Svaren, are both listed as advisers to that company.

Here is what they don’t establish:

  • Whether Dubensky was still a director when the Shark Tooth investment was approved, and whether he took part in that decision.
  • Whether advisers to Shark Tooth are paid or hold equity.
  • Who sits on whatever committee runs the venture-philanthropy arm, and what conflict rules it follows.
  • What the CMTA’s other program-related investments are.

Advising a startup while serving on a charity’s board is common in rare-disease research, and expertise is exactly why such people are recruited. That is also why disclosure matters. When a charity invests donors’ money in companies, the people who shaped that policy, and the people who advise the companies, should be named, and their roles in each decision should be on the record.

Questions and Replies

On October 12, 2026, I sent requests for comment on the questions in this post to:

  • Tom Dubensky, through ImmuneSensor Therapeutics’ public contact address
  • Shark Tooth Biotech
  • David Apple

I asked each to reply by November 13, 2026.

He did not say whether Dubensky took part in the investment decision.

David Apple replied by email on October 14, 2026, answering both his own questions and, in part, those sent to Shark Tooth. He said Dubensky was a CMTA director when the CMTA approved its investment in Shark Tooth but was not yet a Shark Tooth scientific adviser, and that Dubensky is no longer on the CMTA board. He did not say whether Dubensky took part in the investment decision. He said that, as of October 2026, none of Shark Tooth’s advisers had ever received cash or equity compensation from the company. Shark Tooth’s team page then listed Dubensky as “Board of CMTA”; by October 19, 2026, it called him a “Former CMTA Board Member.” His account also doesn’t explain why the CMTA’s Winter 2025 report lists Dubensky as a special adviser to the board when its board page doesn’t. Apple’s full replies are published with “Canada’s CMT1A Research Partnership: Who Funds It, and Who Gets the Rights?”

I sent Apple follow-up questions on October 15, including whether Dubensky took part in the CMTA’s decision to invest, when Dubensky left the board, and whether he has been a special adviser to it. Apple replied the same day only to correct his timeline: he discussed the idea of Shark Tooth with the CMTA board in February 2024 and incorporated the company in September 2024. He said he would not continue the correspondence.

The CMTA’s chief executive, Sue Bruhn, replied to my questions on October 14 without addressing Dubensky’s role. She wrote that all CMTA directors and STAR advisory board members “fill out written conflict of interest statements, and are required to share any potential conflicts with any topic at every meeting,” and that members with conflicts “are excluded from all discussions and decisions around that topic.” Apple says Dubensky wasn’t yet a Shark Tooth adviser when the investment was approved. Neither of them said when he became one, or whether he declared a conflict over Shark Tooth at any CMTA meeting.

Tom Dubensky had not replied by the November 13 deadline, and Shark Tooth Biotech’s separate request was answered only through Apple’s replies. I will add any later reply with a dated note.

November 17, 2026: Update. Dubensky’s LinkedIn profile, which I read on November 17, lists him as a CMTA board member from June 2016 to March 2026. It also says he was ImmuneSensor’s president and CEO from April 2024 to September 2026, and has been a part-time adviser to its chairman since October 2026. So he had left the CEO role before I wrote to ImmuneSensor’s contact address on October 12. His profile does not mention Shark Tooth Biotech.

This post is based on public records checked between October 11 and November 8, 2026, and on replies received by November 8. If anything here is wrong, tell me, and I will correct it with a dated note.

Notes

  1. Charcot-Marie-Tooth Association, “CMT Patient and Research Summit Speaker Bios” (2022), https://cmtausa.org/2022-cmt-patient-and-research-summit-bios-final. ↩︎
  2. ImmuneSensor Therapeutics, “ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive Thomas W. Dubensky, Jr., Ph.D. as Chief Executive Officer,” press release, GlobeNewswire, May 1, 2024, https://www.globenewswire.com/news-release/2024/05/01/2873194/0/en/ImmuneSensor-Therapeutics-Appoints-Veteran-Biopharma-Executive-Thomas-W-Dubensky-Jr-Ph-D-as-Chief-Executive-Officer.html. ↩︎
  3. Charcot-Marie-Tooth Association, Form 990 returns for tax years 2017 through 2024, Part VII, Section A, via ProPublica Nonprofit Explorer, accessed October 11, 2026, https://projects.propublica.org/nonprofits/organizations/222480896. Dubensky is listed as “Director” for 2017 through 2023 and as “Board Member” for 2024, with no start or end date. He does not appear on the 2016 return. ↩︎
  4. Charcot-Marie-Tooth Association, The CMTA Report 34, no. 2 (Summer 2019): 2, https://cmtausa.org/download/4171. The masthead lists “Thomas W. Dubensky, Jr., PhD” under Board of Directors. ↩︎
  5. Charcot-Marie-Tooth Association, Form 990 for tax year 2025, filed May 15, 2026, Part VII, Section A, and Part VI, line 1a, via ProPublica Nonprofit Explorer, https://projects.propublica.org/nonprofits/full_text/202631349349313743/IRS990. ↩︎
  6. Charcot-Marie-Tooth Association, “Board of Directors,” accessed October 11, 2026, https://cmtausa.org/board-of-directors/. ↩︎
  7. Charcot-Marie-Tooth Association, The CMTA Report, Winter 2025 (2025), https://cmtausa.org/wp-content/uploads/2026/01/2025-Winter-CMTA-Report_Download_small.pdf. ↩︎
  8. Charcot-Marie-Tooth Association, “Board of Directors,” archived September 16, 2025, and April 12, 2026, Internet Archive, https://web.archive.org/web/20250916040613/https://cmtausa.org/board-of-directors/ and https://web.archive.org/web/20260412085630/https://cmtausa.org/board-of-directors/. ↩︎
  9. Charcot-Marie-Tooth Association, “CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy,” press release, ACCESSWIRE, November 16, 2023, republished by BioSpace, https://www.biospace.com/cmta-announces-participation-in-seed-extension-round-for-armatus-bio-for-novel-cmt1a-gene-therapy. ↩︎
  10. Charcot-Marie-Tooth Association, Form 990 for tax year 2025, Part X, line 13, “Investments—program-related,” via ProPublica Nonprofit Explorer, https://projects.propublica.org/nonprofits/full_text/202631349349313743/IRS990. The return reports $281,041 at the start of 2025 and $403,066 at the end. ↩︎
  11. Delaware Department of State, Division of Corporations, “Shark Tooth Biotech Corporation, File Number 5208523,” Entity Search, accessed October 15, 2026, https://icis.corp.delaware.gov/ecorp/entitysearch/namesearch.aspx; California Secretary of State, Shark Tooth Biotech Corporation (entity number 6400890), “Statement and Designation – Out-of-State Stock Corporation,” filed September 25, 2024, “Statement of Information,” filed September 22, 2025, and “Statement of Information,” filed July 21, 2026, bizfile Online, https://bizfileonline.sos.ca.gov/search/business. ↩︎
  12. Shark Tooth Biotech, “Our Story,” accessed October 10, 2026, https://www.sharktooth.bio/our-story. ↩︎
  13. Charcot-Marie-Tooth Association, Form 990 for tax year 2023, Part VII, Section A, via ProPublica Nonprofit Explorer, https://projects.propublica.org/nonprofits/organizations/222480896. David Apple is listed as “Director (from Apr. 2023).” ↩︎
  14. Charcot-Marie-Tooth Association, Form 990 for tax year 2025, Schedule L, Part IV, via ProPublica Nonprofit Explorer, https://projects.propublica.org/nonprofits/full_text/202631349349313743/IRS990ScheduleL. ↩︎
  15. Charcot-Marie-Tooth Association, Audited Financial Statements, December 31, 2025, Note H, “Related Party Transaction – Mission-Related Investment,” 11, https://cmtausa.org/wp-content/uploads/2026/05/2025-Audited-Financials.pdf. ↩︎
  16. Shark Tooth Biotech, “Our Team,” accessed October 11, 2026, https://www.sharktooth.bio/our-team. ↩︎
  17. Charcot-Marie-Tooth Association, Form 990 for tax year 2025, filed May 15, 2026, Part VII, Section A, and Part III, via ProPublica Nonprofit Explorer, https://projects.propublica.org/nonprofits/full_text/202631349349313743/IRS990. ↩︎

Bibliography

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *